<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We conducted a phase II trial of doxercalciferol, a <z:chebi fb="0" ids="28934">vitamin D2</z:chebi> analogue, in 15 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Each received doxercalciferol 12.5 microg orally daily for 12 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Nine of 15 patients completed the prescribed course and of these, six had stable disease </plain></SENT>
<SENT sid="3" pm="."><plain>No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) had a marked rise in monocytes on study </plain></SENT>
<SENT sid="5" pm="."><plain>Overall the treatment was well tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>One patient was removed from study due to <z:hpo ids='HP_0003072'>hypercalcemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that short-term treatment with doxercalciferol has limited activity in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>